Ex Vivo and In Vivo Characterization of Interpolymeric Blend/Nanoenabled Gastroretentive Levodopa Delivery Systems
One approach for delivery of narrow absorption window drugs is to formulate gastroretentive drug delivery systems. This study was undertaken to provide insight into in vivo performances of two gastroretentive systems (PXLNET and IPB matrices) in comparison to Madopar® HBS capsules. The pig model was...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Parkinson's Disease |
| Online Access: | http://dx.doi.org/10.1155/2017/7818123 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849687036336799744 |
|---|---|
| author | Ndidi C. Ngwuluka Yahya E. Choonara Girish Modi Lisa C. du Toit Pradeep Kumar Leith Meyer Tracy Snyman Viness Pillay |
| author_facet | Ndidi C. Ngwuluka Yahya E. Choonara Girish Modi Lisa C. du Toit Pradeep Kumar Leith Meyer Tracy Snyman Viness Pillay |
| author_sort | Ndidi C. Ngwuluka |
| collection | DOAJ |
| description | One approach for delivery of narrow absorption window drugs is to formulate gastroretentive drug delivery systems. This study was undertaken to provide insight into in vivo performances of two gastroretentive systems (PXLNET and IPB matrices) in comparison to Madopar® HBS capsules. The pig model was used to assess gastric residence time and pharmacokinetic parameters using blood, cerebrospinal fluid (CSF), and urine samples. Histopathology and cytotoxicity testing were also undertaken. The pharmacokinetic parameters indicated that levodopa was liberated from the drug delivery systems, absorbed, widely distributed, metabolized, and excreted. Cmax were 372.37, 257.02, and 461.28 ng/mL and MRT were 15.36, 14.98, and 13.30 for Madopar HBS capsules, PXLNET, and IPB, respectively. In addition, X-ray imaging indicated that the gastroretentive systems have the potential to reside in the stomach for 7 hours. There was strong in vitro-in vivo correlation for all formulations with r2 values of 0.906, 0.935, and 0.945 for Madopar HBS capsules, PXLNET, and IPB, respectively. Consequently, PXLNET and IPB matrices have pertinent potential as gastroretentive systems for narrow absorption window drugs (e.g., L-dopa) and, in this application specifically, enhanced the central nervous system and/or systemic bioavailability of such drugs. |
| format | Article |
| id | doaj-art-020f66f9df2a4c298d6307ecacc6891c |
| institution | DOAJ |
| issn | 2090-8083 2042-0080 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Parkinson's Disease |
| spelling | doaj-art-020f66f9df2a4c298d6307ecacc6891c2025-08-20T03:22:27ZengWileyParkinson's Disease2090-80832042-00802017-01-01201710.1155/2017/78181237818123Ex Vivo and In Vivo Characterization of Interpolymeric Blend/Nanoenabled Gastroretentive Levodopa Delivery SystemsNdidi C. Ngwuluka0Yahya E. Choonara1Girish Modi2Lisa C. du Toit3Pradeep Kumar4Leith Meyer5Tracy Snyman6Viness Pillay7Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, 7 York Road, Parktown 2193, South AfricaWits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, 7 York Road, Parktown 2193, South AfricaDepartment of Neurology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, 7 York Road, Parktown 2193, South AfricaWits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, 7 York Road, Parktown 2193, South AfricaWits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, 7 York Road, Parktown 2193, South AfricaDepartment of Paraclinical Sciences, Faculty of Veterinary Science, University of Pretoria, Pretoria, South AfricaNational Laboratory Services, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, 7 York Road, Parktown 2193, South AfricaWits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, 7 York Road, Parktown 2193, South AfricaOne approach for delivery of narrow absorption window drugs is to formulate gastroretentive drug delivery systems. This study was undertaken to provide insight into in vivo performances of two gastroretentive systems (PXLNET and IPB matrices) in comparison to Madopar® HBS capsules. The pig model was used to assess gastric residence time and pharmacokinetic parameters using blood, cerebrospinal fluid (CSF), and urine samples. Histopathology and cytotoxicity testing were also undertaken. The pharmacokinetic parameters indicated that levodopa was liberated from the drug delivery systems, absorbed, widely distributed, metabolized, and excreted. Cmax were 372.37, 257.02, and 461.28 ng/mL and MRT were 15.36, 14.98, and 13.30 for Madopar HBS capsules, PXLNET, and IPB, respectively. In addition, X-ray imaging indicated that the gastroretentive systems have the potential to reside in the stomach for 7 hours. There was strong in vitro-in vivo correlation for all formulations with r2 values of 0.906, 0.935, and 0.945 for Madopar HBS capsules, PXLNET, and IPB, respectively. Consequently, PXLNET and IPB matrices have pertinent potential as gastroretentive systems for narrow absorption window drugs (e.g., L-dopa) and, in this application specifically, enhanced the central nervous system and/or systemic bioavailability of such drugs.http://dx.doi.org/10.1155/2017/7818123 |
| spellingShingle | Ndidi C. Ngwuluka Yahya E. Choonara Girish Modi Lisa C. du Toit Pradeep Kumar Leith Meyer Tracy Snyman Viness Pillay Ex Vivo and In Vivo Characterization of Interpolymeric Blend/Nanoenabled Gastroretentive Levodopa Delivery Systems Parkinson's Disease |
| title | Ex Vivo and In Vivo Characterization of Interpolymeric Blend/Nanoenabled Gastroretentive Levodopa Delivery Systems |
| title_full | Ex Vivo and In Vivo Characterization of Interpolymeric Blend/Nanoenabled Gastroretentive Levodopa Delivery Systems |
| title_fullStr | Ex Vivo and In Vivo Characterization of Interpolymeric Blend/Nanoenabled Gastroretentive Levodopa Delivery Systems |
| title_full_unstemmed | Ex Vivo and In Vivo Characterization of Interpolymeric Blend/Nanoenabled Gastroretentive Levodopa Delivery Systems |
| title_short | Ex Vivo and In Vivo Characterization of Interpolymeric Blend/Nanoenabled Gastroretentive Levodopa Delivery Systems |
| title_sort | ex vivo and in vivo characterization of interpolymeric blend nanoenabled gastroretentive levodopa delivery systems |
| url | http://dx.doi.org/10.1155/2017/7818123 |
| work_keys_str_mv | AT ndidicngwuluka exvivoandinvivocharacterizationofinterpolymericblendnanoenabledgastroretentivelevodopadeliverysystems AT yahyaechoonara exvivoandinvivocharacterizationofinterpolymericblendnanoenabledgastroretentivelevodopadeliverysystems AT girishmodi exvivoandinvivocharacterizationofinterpolymericblendnanoenabledgastroretentivelevodopadeliverysystems AT lisacdutoit exvivoandinvivocharacterizationofinterpolymericblendnanoenabledgastroretentivelevodopadeliverysystems AT pradeepkumar exvivoandinvivocharacterizationofinterpolymericblendnanoenabledgastroretentivelevodopadeliverysystems AT leithmeyer exvivoandinvivocharacterizationofinterpolymericblendnanoenabledgastroretentivelevodopadeliverysystems AT tracysnyman exvivoandinvivocharacterizationofinterpolymericblendnanoenabledgastroretentivelevodopadeliverysystems AT vinesspillay exvivoandinvivocharacterizationofinterpolymericblendnanoenabledgastroretentivelevodopadeliverysystems |